Literature DB >> 2298672

Evaluation of upper respiratory tract function during strenuous exercise in racehorses.

E A Morris1, H J Seeherman.   

Abstract

Forty-six racehorses with a history of poor performance underwent endoscopic evaluation of laryngeal and pharyngeal function while exercising on a high-speed treadmill. This evaluation allowed the definitive diagnosis of intermittent or continual upper respiratory tract obstruction as a cause of poor performance, as well as the documentation of the dynamic functional anatomy of the obstruction. Ten of the horses (22%) were determined to have a functional abnormality of the upper respiratory tract. These abnormalities included epiglottic entrapment (1 horse), persistent dorsal displacement of the soft palate during exercise (4 horses), and left laryngeal hemiplegia (5 horses). Thirty-two horses were observed to have signs of left laryngeal hemiparesis (asynchronous arytenoid movement) at rest that did not impair full laryngeal abduction during strenuous exercise.

Entities:  

Mesh:

Year:  1990        PMID: 2298672

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  3 in total

1.  Treadmill endoscopic findings in 15 racehorses presented for poor performance.

Authors:  F Ferrucci; E Zucca; V Di Fabio; E Ferro
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

2.  Temporary suppression of cell-mediated immunity in standardbred horses with decreased athletic capacity.

Authors:  M Jensen-Waern; S G Persson; A Nordengrahn; M Mérza; C Fossum
Journal:  Acta Vet Scand       Date:  1998       Impact factor: 1.695

3.  Genomic analysis establishes correlation between growth and laryngeal neuropathy in Thoroughbreds.

Authors:  Adam R Boyko; Samantha A Brooks; Ashley Behan-Braman; Marta Castelhano; Elizabeth Corey; Kyle C Oliveira; June E Swinburne; Rory J Todhunter; Zhiwu Zhang; Dorothy M Ainsworth; Norman Edward Robinson
Journal:  BMC Genomics       Date:  2014-04-03       Impact factor: 3.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.